Top

The Journal of Headache and Pain

Published in:

Open Access 01-12-2022 | Migraine | Research article

Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition

Authors: Doga Vuralli, Burak Arslan, Elif Topa, Andreia Lopes de Morais, Ozlem Gulbahar, Cenk Ayata, Hayrunnisa Bolay

Published in: The Journal of Headache and Pain | Issue 1/2022

Abstract

Background/aim

Certain constituents in migraine food triggers and non-steroidal anti-inflammatory drugs (NSAIDs) inhibit sulfotransferases (SULTs) that detoxify drugs/chemicals and play role in the metabolism of neurotransmitters. We aimed to dissect SULT1A1 modulation of CSD susceptibility and behavior in an in vivo experimental model using hesperidin, a SULT1A1 inhibitor found in citrus fruits (known migraine triggers) and mefenamic acid (SULT1A1 inhibitor), an NSAID to simulate medication overuse.

Methods

Hesperidin was used as SULT1A1 inhibitor found in citrus fruits, known migraine triggers and mefenamic acid (NSAID), another SULT1A1 inhibitor, was used to induce MO in rats. The groups were; 1) Hesperidin (ip) or its vehicle-DMSO (ip) 2) Chronic (4 weeks) mefenamic acid (ip) or its vehicle (ip) 3) Chronic mefenamic acid+hesperidin (ip) or DMSO (ip). CSD susceptibility was evaluated and behavioral testing was performed. SULT1A1 enzyme activity was measured in brain samples.

Results

Single-dose of hesperidin neither changed CSD susceptibility nor resulted in any behavioral change. Chronic mefenamic acid exposure resulted in increased CSD susceptibility, mechanical-thermal hypersensitivity, increased head shake, grooming and freezing and decreased locomotion. Single dose hesperidin administration after chronic mefenamic acid exposure resulted in increased CSD susceptibility and mechanical-thermal hypersensitivity, increased freezing and decreased locomotion. SULT1A1 enzyme activity was lower in mefenamic acid and mefenamic acid+hesperidin groups compared to their vehicles.

Conclusion

Mefenamic acid and hesperidin have synergistic effect in modulating CSD susceptibility and pain behavior. Sulfotransferase inhibition may be the common mechanism by which food triggers and NSAIDs modulate migraine susceptibility. Further investigations regarding human provocation studies using hesperidin in migraine patients with medication overuse are needed.

Westergaard ML, Hansen EH, Glümer C, Olesen J, Jensen RH (2014) Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 34(6):409–425. https://doi.org/10.1177/0333102413512033CrossRefPubMed

Eagle K (2012) Toxicological effects of red wine, orange juice, and other dietary SULT1A inhibitors via excess catecholamines. Food Chem Toxicol 50(6):2243–2249. https://doi.org/10.1016/j.fct.2012.03.004CrossRefPubMed

Davis BA, Dawson B, Boulton AA, Yu PH, Durden DA (1987) Investigation of some biological trait markers in migraine: deuterated tyramine challenge test, monoamine oxidase, phenolsulfotransferase and plasma and urinary biogenic amine and acid metabolite levels. Headache. 27(7):384–389. https://doi.org/10.1111/j.1526-4610.1987.hed2707384.xCrossRefPubMed

Marazziti D, Palego L, Dell'Osso L, Batistini A, Cassano GB, Akiskal HS (1996) Platelet sulfotransferase in different psychiatric disorders. Psychiatry Res 65(2):73–78. https://doi.org/10.1016/s0165-1781(96)02898-3CrossRefPubMed

Alam Z, Coombes N, Waring RH, Williams AC, Steventon GB (1997) Platelet sulphotransferase activity, plasma sulphate levels and sulphation capacity in patients with migraine and tension headache. Cephalalgia. 17(7):761–764. https://doi.org/10.1046/j.1468-2982.1997.1707761.xCrossRefPubMed

Jones AL, Roberts RC, Colvin DW, Rubin GL, Coughtrie MW (1995) Reduced platelet phenolsulphotransferase activity towards dopamine and 5-hydroxytryptamine in migraine. Eur J Clin Pharmacol 49(1–2):109–114. https://doi.org/10.1007/bf00192368CrossRefPubMed

Littlewood J, Glover V, Sandler M, Petty R, Peatfield R, Rose FC (1982) Platelet phenolsulphotransferase deficiency in dietary migraine. Lancet. 1(8279):983–986. https://doi.org/10.1016/s0140-6736(82)91990-0CrossRefPubMed

Vietri M, De Santi C, Pietrabissa A, Mosca F, Pacifici GM (2000) Inhibition of human liver phenol sulfotransferase by nonsteroidal anti-inflammatory drugs. Eur J Clin Pharmacol 56(1):81–87. https://doi.org/10.1007/s002280050725CrossRefPubMed

Supornsilpchai W, le Grand SM, Srikiatkhachorn A (2010) Cortical hyperexcitability and mechanism of medication-overuse headache. Cephalalgia. 30(9):1101–1109. https://doi.org/10.1177/0333102409355600CrossRefPubMed

10.

Green AL, Gu P, De Felice M, Dodick D, Ossipov MH, Porreca F (2014) Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. Cephalalgia. 34(8):594–604. https://doi.org/10.1177/0333102413515344CrossRefPubMed

11.

Becerra L, Bishop J, Barmettler G, Xie Y, Navratilova E, Porreca F et al (2016) Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas. J Neurophysiol 115(1):208–217. https://doi.org/10.1152/jn.00632.2015CrossRefPubMed

12.

Sidharthan NP, Minchin RF, Butcher NJ (2013) Cytosolic sulfotransferase 1A3 is induced by dopamine and protects neuronal cells from dopamine toxicity: role of D1 receptor-N-methyl-D-aspartate receptor coupling. J Biol Chem 288(48):34364–34374. https://doi.org/10.1074/jbc.M113.493239CrossRefPubMedPubMedCentral

13.

Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL et al (2006) Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 90(1):5–22. https://doi.org/10.1093/toxsci/kfj061CrossRefPubMed

14.

Ayata C (2013) Pearls and pitfalls in experimental models of spreading depression. Cephalalgia. 33(8):604–613. https://doi.org/10.1177/0333102412470216CrossRefPubMed

15.

Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59(4):652–661. https://doi.org/10.1002/ana.20778CrossRefPubMed

16.

Pellow S, File SE (1986) Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24(3):525–529. https://doi.org/10.1016/0091-3057(86)90552-6CrossRefPubMed

17.

Sayin A, Derinöz O, Yüksel N, Şahin S, Bolay H (2014) The effects of the estrus cycle and citalopram on anxiety-like behaviors and c-fos expression in rats. Pharmacol Biochem Behav 124:180–187. https://doi.org/10.1016/j.pbb.2014.06.002CrossRefPubMed

18.

Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53(1):55–63. https://doi.org/10.1016/0165-0270(94)90144-9CrossRefPubMed

19.

Cook I, Wang T, Falany CN, Leyh TS (2013) High accuracy in silico sulfotransferase models. J Biol Chem 288(48):34494–34501. https://doi.org/10.1074/jbc.M113.510974CrossRefPubMedPubMedCentral

20.

Swinehart DF (1962) The beer-lambert law. J Chem Educ 39(7):333CrossRef

21.

Tepe N, Filiz A, Dilekoz E, Akcali D, Sara Y, Charles A et al (2015) The thalamic reticular nucleus is activated by cortical spreading depression in freely moving rats: prevention by acute valproate administration. Eur J Neurosci 41(1):120–128. https://doi.org/10.1111/ejn.12753CrossRefPubMed

22.

Filiz A, Tepe N, Eftekhari S, Boran HE, Dilekoz E, Edvinsson L et al (2019) CGRP receptor antagonist MK-8825 attenuates cortical spreading depression induced pain behavior. Cephalalgia. 39(3):354–365. https://doi.org/10.1177/0333102417735845CrossRefPubMed

23.

Vuralli D, Wattiez AS, Russo AF, Bolay H (2019) Behavioral and cognitive animal models in headache research. J Headache Pain 20(1):11. https://doi.org/10.1186/s10194-019-0963-6CrossRefPubMedPubMedCentral

24.

Akcali D, Sayin A, Sara Y, Bolay H (2010) Does single cortical spreading depression elicit pain behaviour in freely moving rats? Cephalalgia. 30(10):1195–1206. https://doi.org/10.1177/0333102409360828CrossRefPubMed

25.

Stucky NL, Gregory E, Winter MK, He YY, Hamilton ES, McCarson KE et al (2011) Sex differences in behavior and expression of CGRP-related genes in a rodent model of chronic migraine. Headache. 51(5):674–692. https://doi.org/10.1111/j.1526-4610.2011.01882.xCrossRefPubMedPubMedCentral

26.

Melo-Carrillo A, Lopez-Avila A (2013) A chronic animal model of migraine, induced by repeated meningeal nociception, characterized by a behavioral and pharmacological approach. Cephalalgia. 33(13):1096–1105. https://doi.org/10.1177/0333102413486320CrossRefPubMed

27.

Bates EA, Nikai T, Brennan KC, Fu YH, Charles AC, Basbaum AI et al (2010) Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia. 30(2):170–178. https://doi.org/10.1111/j.1468-2982.2009.01864.xCrossRefPubMedPubMedCentral

28.

Farkas S, Bölcskei K, Markovics A, Varga A, Kis-Varga Á, Kormos V et al (2016) Utility of different outcome measures for the nitroglycerin model of migraine in mice. J Pharmacol Toxicol Methods 77:33–44. https://doi.org/10.1016/j.vascn.2015.09.006CrossRefPubMed

29.

Akçali D, Belen AD, Babacan A, Bolay H (2017) Nitroglycerin challenge induces lateralized headache in nasociliarynerve-ligated rats: implications for chronic migraine. Turk J Med Sci 47(2):681–688. https://doi.org/10.3906/sag-1602-86CrossRefPubMed

30.

Kim SJ, Yeo JH, Yoon SY, Kwon SG, Lee JH, Beitz AJ et al (2018) Differential development of facial and hind paw Allodynia in a nitroglycerin-induced mouse model of chronic migraine: role of capsaicin sensitive primary afferents. Biol Pharm Bull 41(2):172–181. https://doi.org/10.1248/bpb.b17-00589CrossRefPubMed

31.

Belanger S, Ma W, Chabot JG, Quirion R (2002) Expression of calcitonin gene-related peptide, substance P and protein kinase C in cultured dorsal root ganglion neurons following chronic exposure to mu, delta and kappa opiates. Neuroscience. 115(2):441–453. https://doi.org/10.1016/s0306-4522(02)00452-9CrossRefPubMed

32.

De Felice M, Ossipov MH, Wang R, Dussor G, Lai J, Meng ID et al (2010) Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain. 133(Pt 8):2475–2488. https://doi.org/10.1093/brain/awq159CrossRefPubMedPubMedCentral

33.

De Felice M, Ossipov MH, Wang R, Lai J, Chichorro J, Meng I et al (2010) Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol 67(3):325–337. https://doi.org/10.1002/ana.21897CrossRefPubMedPubMedCentral

34.

Zhang M, Liu Y, Zhao M, Tang W, Wang X, Dong Z et al (2017) Depression and anxiety behaviour in a rat model of chronic migraine. J Headache Pain 18(1):27. https://doi.org/10.1186/s10194-017-0736-zCrossRefPubMedPubMedCentral

35.

Wanasuntronwong A, Jansri U, Srikiatkhachorn A (2017) Neural hyperactivity in the amygdala induced by chronic treatment of rats with analgesics may elucidate the mechanisms underlying psychiatric comorbidities associated with medication-overuse headache. BMC Neurosci 18(1):1. https://doi.org/10.1186/s12868-016-0326-zCrossRefPubMedPubMedCentral

36.

Aral LA, ErgÜn MA, Bolay H (2021) Cellular iron storage and trafficking are affected by GTN stimulation in primary glial and meningeal cell culture. Turk J Biol 45(1):46–55. https://doi.org/10.3906/biy-2009-1CrossRefPubMedPubMedCentral

37.

Borkum JM (2016) Migraine triggers and oxidative stress: a narrative review and synthesis. Headache. 56(1):12–35. https://doi.org/10.1111/head.12725CrossRefPubMed

38.

Launay JM, Soliman H, Pradalier A, Dry J, Dreux C (1988) Platelet phenol sulfotransferase activities: a migraine marker? Therapie. 43(4):273–277PubMed

39.

Charbit AR, Akerman S, Goadsby PJ (2010) Dopamine: what's new in migraine? Curr Opin Neurol 23(3):275–281. https://doi.org/10.1097/WCO.0b013e3283378d5cCrossRefPubMed

40.

Gorji A (2001) Spreading depression: a review of the clinical relevance. Brain Res Brain Res Rev 38(1–2):33–60. https://doi.org/10.1016/s0165-0173(01)00081-9CrossRefPubMed

41.

Del Zompo M, Lai M, Loi V, Pisano MR (1995) Dopamine hypersensitivity in migraine: role in apomorphine syncope. Headache. 35(4):222–224. https://doi.org/10.1111/j.1526-4610.1995.hed3504222.xCrossRefPubMed

42.

Blin O, Azulay JP, Masson G, Aubrespy G, Serratrice G (1991) Apomorphine-induced yawning in migraine patients: enhanced responsiveness. Clin Neuropharmacol 14(1):91–95. https://doi.org/10.1097/00002826-199102000-00008CrossRefPubMed

43.

Blau JN (1992) Migraine: theories of pathogenesis. Lancet. 339(8803):1202–1207. https://doi.org/10.1016/0140-6736(92)91140-4CrossRefPubMed

44.

Peroutka SJ (1997) Dopamine and migraine. Neurology. 49(3):650–656. https://doi.org/10.1212/wnl.49.3.650CrossRefPubMed

45.

Marmura MJ (2012) Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 14(1):27–35. https://doi.org/10.1007/s11940-011-0150-9CrossRefPubMed

46.

Doğanay Aydin H, Vuralli D, Akçali DT, Bolay H (2017) Metoclopramide inhibits trigeminovascular activation:evidence for effective acute attack treatment in migraine. Turk J Med Sci 47(1):343–347. https://doi.org/10.3906/sag-1601-195CrossRefPubMed

47.

D'Andrea G, Granella F, Perini F, Farruggio A, Leone M, Bussone G (2006) Platelet levels of dopamine are increased in migraine and cluster headache. Headache. 46(4):585–591. https://doi.org/10.1111/j.1526-4610.2006.00407.xCrossRefPubMed

48.

D'Andrea G, D'Arrigo A, Dalle Carbonare M, Leon A (2012) Pathogenesis of migraine: role of neuromodulators. Headache. 52(7):1155–1163. https://doi.org/10.1111/j.1526-4610.2012.02168.xCrossRefPubMed

49.

Nagel-Leiby S, Welch KM, D'Andrea G, Grunfeld S, Brown E (1990) Event-related slow potentials and associated catecholamine function in migraine. Cephalalgia. 10(6):317–329. https://doi.org/10.1046/j.1468-2982.1990.1006317.xCrossRefPubMed

50.

Castillo J, Martínez F, Suárez C, Naveiro J, Lema M, Noya M (1996) Cerebrospinal fluid tyrosine and 3,4-dihydroxyphenylacetic acid levels in migraine patients. Cephalalgia. 16(1):56–61. https://doi.org/10.1046/j.1468-2982.1996.1601056.xCrossRefPubMed

51.

D'Andrea G, Leon A (2010) Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond. Neurol Sci 31(Suppl 1):S1–S7. https://doi.org/10.1007/s10072-010-0267-8CrossRefPubMed

Title: Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition
Authors: Doga Vuralli
Burak Arslan
Elif Topa
Andreia Lopes de Morais
Ozlem Gulbahar
Cenk Ayata
Hayrunnisa Bolay
Publication date: 01-12-2022
Publisher: Springer Milan
Keywords: Migraine
Mefenamic Acid
Published in: The Journal of Headache and Pain / Issue 1/2022
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-022-01405-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition

Abstract

Background/aim

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background/aim

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences

The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials

Long term evaluation of a multidisciplinary trigeminal neuralgia service

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

Expression of vasopressin and its receptors in migraine-related regions in CNS and the trigeminal system: influence of sex

Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies